Current Report Filing (8-k)
December 31 2020 - 4:25PM
Edgar (US Regulatory)
0001680048
false
0001680048
2020-12-31
2020-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 31, 2020
Mustang Bio, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
001-38191
|
|
47-3828760
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
377 Plantation Street
Worcester, Massachusetts 01605
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
MBIO
|
|
NASDAQ Global Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On
December 31, 2020, Mustang Bio, Inc. (the “Company”) amended its At Market Issuance Sales Agreement by and among the
Company, B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald & Co., National Securities Corporation
and Oppenheimer & Co. Inc., dated July 27, 2018, as amended on July 20, 2020 (the “Agreement”) to add H.C.
Wainwright & Co., LLC as an agent. Amendment No. 2 to the Agreement is attached hereto as Exhibit 1.1 and incorporated by reference
herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished as part of this report:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 31, 2020
|
Mustang Bio, Inc.
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Manuel Litchman, M.D.
|
|
|
Manuel Litchman, M.D.
|
|
|
President and Chief Executive Officer
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024